trending Market Intelligence /marketintelligence/en/news-insights/trending/tPSLVVKW_hoPl7DNcHMjrw2 content esgSubNav
In This List

INmune Bio to raise $20M from Lincoln Park to fund drug pipeline

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


INmune Bio to raise $20M from Lincoln Park to fund drug pipeline

INmune Bio Inc. received an investment commitment from Chicago-based institutional investor Lincoln Park Capital Fund LLC, which has agreed to buy $20 million worth of the company's shares over a 24-month period, including an initial investment of $300,000.

INmune Bio, a clinical-stage biotechnology company focused on developing medicines for cancer, will use the proceeds for the development of its drug candidates into phase 2 clinical studies. Amount raised through the sale of shares to Lincoln Park will also support expenses related to general corporate purposes.